» Articles » PMID: 29526543

Synergy Between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment

Overview
Journal Cell Metab
Publisher Cell Press
Date 2018 Mar 13
PMID 29526543
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

The lung presents a highly oxidative environment, which is tolerated through engagement of tightly controlled stress response pathways. A critical stress response mediator is the transcription factor nuclear factor erythroid-2-related factor 2 (NFE2L2/NRF2), which is negatively regulated by Kelch-like ECH-associated protein 1 (KEAP1). Alterations in the KEAP1/NRF2 pathway have been identified in 23% of lung adenocarcinomas, suggesting that deregulation of the pathway is a major cancer driver. We demonstrate that inactivation of Keap1 and Pten in the mouse lung promotes adenocarcinoma formation. Notably, metabolites identified in the plasma of Keap1/Pten tumor-bearing mice indicate that tumorigenesis is associated with reprogramming of the pentose phosphate pathway. Furthermore, the immune milieu was dramatically changed by Keap1 and Pten deletion, and tumor regression was achieved utilizing immune checkpoint inhibition. Thus, our study highlights the ability to exploit both metabolic and immune characteristics in the detection and treatment of lung tumors harboring KEAP1/NRF2 pathway alterations.

Citing Articles

NRP1 overexpression potentially enhances osimertinib resistance in NSCLC via activation of the PI3K/AKT signaling pathway.

Wang Y, Wang B, Zhou L, Wan Y, Zheng Y, Zhou L Am J Cancer Res. 2025; 14(12):5680-5696.

PMID: 39803652 PMC: 11711526. DOI: 10.62347/RLVZ6860.


CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A Nature. 2024; 635(8038):462-471.

PMID: 39385035 PMC: 11560846. DOI: 10.1038/s41586-024-07943-7.


Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma.

Liang Y, Maeda O, Kondo C, Nishida K, Ando Y PLoS One. 2024; 19(7):e0307580.

PMID: 39037971 PMC: 11262633. DOI: 10.1371/journal.pone.0307580.


Development and validation of matrix metalloproteinase for predicting prognosis and tumour microenvironment immune profiles in uterine corpus endometrial carcinoma.

Su H, Yang Y, Li C, Li J, Lv H, Jia X J Cancer. 2024; 15(12):4020-4039.

PMID: 38911387 PMC: 11190773. DOI: 10.7150/jca.91277.


Protective effect of dexmedetomidine against delayed bone healing caused by morphine via PI3K/Akt mediated Nrf2 antioxidant defense system.

Lou Y, Zou L, Shen Z, Zheng J, Lin Y, Zhang Z Front Pharmacol. 2024; 15:1396713.

PMID: 38863982 PMC: 11165180. DOI: 10.3389/fphar.2024.1396713.